Results
|
1.
|
Deleterious BRCA1/2 mutations in an urban population of Black women. MedStar authors:
- Fries, Melissa
- Lynce, Filipa
Year: 2015
Citation: - Breast Cancer Research & Treatment. 153(1):201-9, 2015 Aug.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - DeMarco T, Fries M, Isaacs C, Lynce F, Peshkin BN, Smith KL, Stein J, Wang H, Wang Y
|
|
2.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors:
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D
|
|
3.
|
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. MedStar authors:
- Gallagher, Christopher
- Lynce, Filipa
- Ottaviano, Yvonne
Year: 2021
Citation: - Clinical Cancer Research. 27(21):5810-5817, 2021 11 01.
Institution:
- MedStar Franklin Square Medical Center
- Washington Cancer Institute
Medline publication type:
All authors: - Althouse SK, Ballinger TJ, Bauchle A, Dong Z, Gallagher C, Liu JY, Lynce F, Masters AR, Miller KD, Ottaviano YL, Perkins SM, Sardesai SD, Schneider BP, Storniolo AM, Stratford RE Jr, Thomas A, Zhang JT
|
|
4.
|
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. MedStar authors:
- Chitalia, Ami
- Gallagher, Christopher
- Schlam, Ilana
- Swain, Sandra M
- Tiwari, Shruti
Year: 2024
Citation: - Nature communications . 15(1):2691, 2024 Mar 27.
Institution: - Washington Cancer Institute
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C
|
|
5.
|
|
|
6.
|
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. MedStar authors: - Swain, Sandra M MedStar Health
Year: 2024
Citation: - Annals of Oncology. 35(7):630-642, 2024 Jul.
Department: - Associate Dean for Research Development
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Dent R, Andre F, Goncalves A, Martin M, Schmid P, Schutz F, Kummel S, Swain SM, Bilici A, Loirat D, Villalobos Valencia R, Im SA, Park YH, De Laurentis M, Colleoni M, Guarneri V, Bianchini G, Li H, Kirchmayer Machackova Z, Mouta J, Deurloo R, Gan X, Fan M, Mani A, Swat A, Cortes J
|